Social News
Written by: Li Enci
2021-02-16 21:52
Last update date: 2021-02-16 22:00
The New Coronary Pneumonia Vaccine Advisory Expert Committee held a press conference today (16th).
The convener of the committee, Liu Zexing, said that the committee believes that the benefit of Kexing vaccine is higher than the possible risk and will recommend it to the Food and Health Bureau for emergency use.
The report shows that the overall protection rate of the vaccine is 50.66% (prevention rate), while the protection rate of two injections 28 days apart has increased to 62.3%.
Participants are mainly 18 to 60 years old. The data does not include the effective rate of vaccinations for the elderly.
Among the approximately 12 million people who have been vaccinated with Kexing vaccine, six adults have painful needles; half have headaches; and half have diarrhea.
As for when the Kexing vaccine will arrive in Hong Kong, Liu Zexing said he did not know.
▼ Kexing vaccine needs seven steps from the laboratory to the market▼
+9
+9
+9
Liu Zexing said that Kexing submitted the third phase of the clinical test report data from the second (13th) to the fourth (15th) of the Lunar New Year. There were 9,500 participants in the test, mainly people aged 18 to 60.
The overall protection rate of the vaccine in reducing symptomatic infections (i.e. prevention of disease) was 50.66%, while the protection rate of two injections 28 days apart increased to 62.3%.
Therefore, the 12 members of the committee agreed that the benefit of Kexing vaccine is higher than the risk, and recommended that the two injections should be administered 28 days apart.
The first generation of vaccines to help prevent disease is worth fighting
Xu Shuchang, a member of the Vaccine Advisory Expert Committee, pointed out that the first-generation vaccine is not necessarily the best, and it is not 100% prevention of infection, but it can effectively reduce symptomatic infections without serious side effects. "They are all worthy of vaccines.
As for who is suitable for the Kexing vaccine, Liu Zexing said that the third phase of the vaccine clinical study will not invite the elderly to participate at the beginning, but people aged 18 to 60.
The appropriate age group of Kexing vaccine will be discussed in detail by the Scientific Committee of the Department of Health. There must be a local mechanism to review the safety of the vaccine for people over 60 years of age.
He added that the first and second phase clinical studies of Kexing vaccine showed that it is safe for people over 60 years old.
▼The epidemic slows down on the seventh day of the first day of the year (February 18) social distancing measures are conditionally relaxed▼
+15
+15
+15
15% had diarrhea and 1.4% had rash
Regarding the common side effects of Kexing, Xu Shuchang said that 11.89 million people have been vaccinated with Kexing vaccine, of which about six adults will experience pain at the injection site; half will have headaches, but the symptoms will disappear within one to two days after the injection.
In terms of other side effects, 19% had muscle weakness; 15% had diarrhea; 13% had nausea; 2.8% had nausea; 1.4% had rash.
As for the serious complications, 44 people had facial paralysis and two had Gibb's disease. Xu said the number was far lower than the background incidence rate.
Liu Zexing also said that the committee will write a report within a week, recommending the emergency use of Kexing vaccine to the government, and the public will be able to read the simple data by then.
As for when Kexing Vaccine will arrive in Hong Kong, Liu said that he "has no inside information." I wonder if Kexing Vaccine will arrive in Hong Kong earlier than the German BioNTech vaccine.
This time the committee approved the emergency use of Koxing vaccine earlier than the WHO.
Liu Zexing emphasized that Kexing Vaccine passed the minimum threshold for emergency use of vaccine approved by the WHO, which is a 50% protection rate.
The WHO lists 25 questions about the effectiveness and safety of vaccines. Kexing’s report cannot answer all of them. For example, the effectiveness of vaccinations for people who have been diagnosed, "I believe that many vaccines have no relevant data." If the WHO later discovers that there is a problem with the vaccine. , The committee can review relevant data at any time and review the recommended decision.
Together with the Kexing vaccine, local experts have recommended the German BioNTech/Fosun (also known as Fubitai) for emergency use of two new crown vaccines in Hong Kong.
The third paragraph has ordered the vaccine-AstraZeneca/Oxford Vaccine in the UK has not yet submitted an emergency use application to the Hong Kong government.
▼The side effects of the vaccine protection rate of Kexing, BioNTech Fosun and AstraZeneca▼
+2
+2
+2
Kexing Vaccine｜Expert consultants recommended that the government use the second dose 28 days apart, the effectiveness of 62.3%
News from the Hospital Authority's Seven New Crown Vaccination Center: More than 30 doctors inject one person in 4 minutes
New Coronary Vaccine | The Advisory Expert Committee of Kexing Supplementary Information During Chinese New Year Meeting Today to Discuss
New Crown Vaccine｜News: Vaccination centers in 18 districts can be vaccinated immediately for those over 60 years old with priority
New Coronary Pneumonia | Israel's 600,000 people study results of Pfizer vaccine effective as high as 94%
New crown pneumonia new crown vaccine China Kexing new crown vaccine side effects
